Education
About Us
Working with TipRanks
Follow Us
NeuroPace (NPCE)
NASDAQ:NPCE
NPCE Stock Chart & Stats
$14.56
-$0.66(-5.31%)
At close: 4:00 PM EST
$14.56
-$0.66(-5.31%)
Day’s Range― - ―
52-Week Range$7.56 - $18.98
Previous CloseN/A
Volume21.31K
Average Volume (3M)165.68K
Market Cap
$485.63M
Enterprise Value$536.16M
Total Cash (Recent Filing)$60.01M
Total Debt (Recent Filing)$71.18M
Price to Earnings (P/E)―
Beta0.42
Next Earnings
Mar 03, 2026EPS Estimate
-0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.11
Shares Outstanding33,307,735
10 Day Avg. Volume137,986
30 Day Avg. Volume165,679
Financial Highlights & Ratios
PEG Ratio0.45
Price to Book (P/B)40.67
Price to Sales (P/S)4.08
P/FCF Ratio-17.85
Enterprise Value/Market Cap1.10
Enterprise Value/Revenue5.65
Enterprise Value/Gross Profit7.36
Enterprise Value/Ebitda-35.37
Forecast
1Y Price Target
$20.00Price Target Upside37.36% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.76
Revenue Forecast (FY)$98.85M
Bulls Say, Bears Say
Bulls Say
Corporate Focus And Portfolio SimplificationReporting noncore DIXI results as discontinued operations signals management focus on the core neuromodulation business, potentially improving resource allocation toward growth drivers.
Profitability And Gross Margin ImprovementStrategic emphasis on higher‑margin personalized neuromodulation combined with strong demand for the RNS system could lift gross margins and support improved profitability.
Valuation And Analyst SentimentAnalyst raised the valuation multiple and increased the price target on expectations that potential label expansion could boost commercial upside, which may bolster investor confidence in the stock.
Bears Say
Clinical Trial Primary Endpoint MissThe pivotal study did not achieve statistical significance on its primary effectiveness endpoint, creating concern about the robustness of evidence needed to expand clinical indications.
Mixed Trial Results And Evidence UncertaintyMissing the primary endpoint at the 12‑month analysis, despite positive secondary outcomes, raises questions about consistency of benefit and could complicate adoption by clinicians.
Regulatory Approval RiskMixed primary and secondary trial results increase the risk that regulators may delay or limit label expansion, which could postpone broader commercial access and revenue potential.
NeuroPace News
NPCE FAQ
What was NeuroPace’s price range in the past 12 months?
NeuroPace lowest stock price was $7.56 and its highest was $18.98 in the past 12 months.
What is NeuroPace’s market cap?
NeuroPace’s market cap is $485.63M.
When is NeuroPace’s upcoming earnings report date?
NeuroPace’s upcoming earnings report date is Mar 03, 2026 which is tomorrow.
How were NeuroPace’s earnings last quarter?
NeuroPace released its earnings results on Nov 04, 2025. The company reported -$0.11 earnings per share for the quarter, beating the consensus estimate of -$0.195 by $0.085.
Is NeuroPace overvalued?
According to Wall Street analysts NeuroPace’s price is currently Undervalued.
Does NeuroPace pay dividends?
NeuroPace does not currently pay dividends.
What is NeuroPace’s EPS estimate?
NeuroPace’s EPS estimate is -0.16.
How many shares outstanding does NeuroPace have?
NeuroPace has 33,307,735 shares outstanding.
What happened to NeuroPace’s price movement after its last earnings report?
NeuroPace reported an EPS of -$0.11 in its last earnings report, beating expectations of -$0.195. Following the earnings report the stock price went up 38.085%.
Which hedge fund is a major shareholder of NeuroPace?
Currently, no hedge funds are holding shares in NPCE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
NeuroPace Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$20.00 (37.36% Upside)
$20.00 (37.36% Upside)
Blogger Sentiment
Bullish
NPCE Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 583.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 14.6%
Last 30 Days ▼ 14.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
5.73%
12-Months-Change
Fundamentals
Return on Equity
-169.27%
Trailing 12-Months
Asset Growth
11.37%
Trailing 12-Months
Company Description
NeuroPace
NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. The company's RNS system also records continuous brain activity data; and enables clinicians to monitor patients in person and remotely. It sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. The company was incorporated in 1997 and is headquartered in Mountain View, California.
NPCE Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue growth, positive adjusted EBITDA, and increased guidance. There were challenges, including the winding down of the DIXI product line and extended timelines for pediatric indication, but these were outweighed by positive developments and strategic progress.View all NPCE earnings summariesNPCE Stock 12 Month Forecast
Average Price Target
$20.00
▲(37.36% Upside)
Technical Analysis
Delcath Systems
―
Senseonics Holdings
―
Tactile Systems Technology
―
RxSight
―
Ceribell, Inc.
―
Ownership Overview
Currently, No data available
---